219例弥漫性大B细胞淋巴瘤免疫表型及遗传学特征分析

管冰心; 潘毅; 房爱菊; 梁艳; 霍颖颖; 孙保存; 王华庆; 付凯; 孟斌

doi:10.3969/j.issn.1000-8179.2012.12.004

219例弥漫性大B细胞淋巴瘤免疫表型及遗传学特征分析

doi: 10.3969/j.issn.1000-8179.2012.12.004

管冰心^①,
潘毅^②,
房爱菊^③,
梁艳^①,
霍颖颖^①,
孙保存^②,
王华庆^②,
付凯^{②, ④},
孟斌^①, ,

①.
山东大学医学院病理学教研室（济南市250012）
②.
天津医科大学附属肿瘤医院病理科，中美淋巴血液肿瘤诊治中心
③.
山东省交通医院病理科
④.
美国内布拉斯加大学医学中心病理学与微生物学系，中美淋巴血液肿瘤诊治中心

详细信息

通讯作者:
孟斌 mengbin@sdu.edu.cn

计量
- 文章访问数: 78
- HTML全文浏览量: 20
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2012-01-29
- 修回日期: 2012-04-02

Immunophenotypes and Cytogenetic Alterations in 219 Cases of Diffuse Large B-cell Lymphoma

Bingxin GUAN^①,
Yi PAN^②,
Aiju FANG^③,
Yan LIANG^①,
Yingying HUO^①,
Baocun SUN^②,
Huaqing WANG^②,
Kai FU^{②, ④},
Bin MENG^{①
, ,}

①.
Department of Pathology, Shandong University School of Medicine, Ji'nan 250012, China
②.
Departments of Pathology and Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Sino-American Center for Lymphoma Diagnosis and Therapy, Tianjin 300060, China
③.
Department of Pathology, Shandong Jiaotong Hospital, Jinan 250031, China
④.
Department of Pathology and Microbiology, 983135 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE 68198-3135

More Information

Corresponding author: Bin MENG; E-mail: mengbin@sdu.edu.cn

摘要

摘要: 目的探讨国内弥漫性大B细胞淋巴瘤（DLBCL）免疫表型分型及BCL-2和BCL-6基因异常的分布情况。方法应用组织芯片和免疫组织化学法及FISH技术对219例DLBCL的免疫表型及BCL-2和BCL-6基因异常进行检测，根据Hans法进行分型；并收集国内7家相关研究报道，进行综合分析。结果本组研究结果：219例DLBCL中，非GCB型（165例，75.3%）显著高于GCB型（54例，24.7%）（P < 0.001）。BCL-2基因异常共49例（25.8%），其中t （14；18）5例（2.6%）均为GCB型；BCL-2基因扩增44例（23.2%），GCB型4例（8.5%），非GCB型40例（28.0%），有显著性差异（P=0.013）。BCL-6基因重排共42例（22.1%），GCB型7例（14.9%），非GCB型35例（24.5%），差异无统计学意义（P=0.189）。BCL-2基因扩增和BCL-6基因重排呈显著负相关（r=-0.180，P=0.013）。8组综合分析：1 259例中非GCB型（879例，69.8%）明显高于GCB型（380例，30.2%）（P < 0.001）；免疫表型中CD10和MUM1阳性率组间差异较小（P=0.047和P=0.048），而BCL-6及BCL-2阳性率组间存在明显差异（P < 0.001）。结论我国DLBCL患者在主要免疫表型和遗传学特征方面具有独特性，对此值得进行深入研究。
- 弥漫性大B细胞淋巴瘤 /
- 免疫表型 /
- BCL-2基因 /
- BCL-6基因
Abstract: Objective To investigate the immunophenotypes, subtypes based on Hans algorithm, and alterations of Bcl-2 and Bcl-6 gene in diffuse large B-cell lymphoma (DLBCL) from Chinese patients. Methods The expression of CD10, BCL-6, MUM1, BCL-2, Ki67 and other markers were detected by immunohistochemistry in tissue microarrays of 219 DLBCL cases. Hans algorithm was applied to classify DLBCL into GCB and non-GCB subtypes. Interphase fluorescence in situ hybridization (FISH) was used to detect the incidence of Bcl-2 and Bcl-6 gene alterations. Other seven studies published in the last two years on DLBCL from China were collected and analyzed. Results (1) This study: ① of 219 DLBCL cases, non-GCB subtype (165 cases, 75.3 %) was significantly more common than GCB subtype (54 cases, 24.7 %) (P < 0.001). ② Bcl-2 gene alteration was detected in 49 cases (25.8 %), including 5 cases with the t (14; 18) (2.6 %) which all existed in GCB subtype, and 44 cases of Bcl-2 amplification (23.2 %) which existed in GCB subtype in 4 cases (8.5 %) and in non-GCB subtype in 40 cases (28.0 %) (P = 0.013). ③ Bcl-6 gene rearrangement was detected in 42 cases (22.1 %), which was in GCB in 7 cases (14.9 %) and was in non-GCB in 35 cases (24.5 %) (P = 0.189). ④ a significant negative correlation between Bcl-2 gene amplification and Bcl-6 gene rearrangement was seen (r = - 0.179 6, P = 0.016 8). Amongst 5 cases having the t (14; 18) translocation, 2 cases accompanied by Bcl-6 gene rearrangement. Forty-nine cases with Bcl-2 gene alterations including translocation and amplification were all but one expressing BCL-2 protein, and there was no significant association between Bcl-6 gene rearrangement and BCL-6 protein expression (P = 0.726). ⑤ there was no significant difference between nodal and extranodal DLBCLs in immunophenotypes, subtypes based on Hans algorithm, and Bcl-2 and Bcl-6 gene alterations (P= 0.462, P= 0.426 andP = 0.167). (2) Comprehensive analysis of eight studies: of the total 1, 259 cases, non-GCB subtype (879 cases, 69.8 %) was significantly more common than GCB subtype (380 cases, 30.2 %) (P < 0.001). Conclusion There are some distinctive features on immunophenotypes and cytogenetic alterations in DLBCL of Chinese patients, which need elucidation by more studies.
- Diffuse large B-cell lymphoma /
- Immunophenotype /
- Bcl-2 gene /
- Bcl-6 gene

HTML全文

表 1 各组研究报道主要免疫表型及分型比较  %（例）

Table 1. Comparative analysis of immunophenotypes and subtypes based on Hans algorithm in this study and seven other published studies

表 2 本组免疫表型及基因异常在GCB、非GCB亚型及结内和结外病例中的分布

Table 2. The distribution of immunophenotypes and gene alterations in GCB vs. non-GCB and nodal vs. extranodal cases

表 3 本组研究BCL-2与BCL-6基因异常之间的相互关系  例

Table 3. The correlations of gene alterations between BCL-2 and BCL-6 in this study

表 4 本组研究免疫表型和基因异常之间的相互关系  例

Table 4. The correlations between the immunophenotypes and gene alterations in this study

参考文献(20)

[1]	Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues[M]. Lyon: IARC Press, 2008: 164.
[2]	Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002, 346(25): 1937-1947. doi: 10.1056/NEJMoa012914
[3]	Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma byimmunohistochemistry using a tissue microarray[J]. Blood, 2004, 103 (1): 275-282. doi: 10.1182/blood-2003-05-1545
[4]	CChoi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypeswith high accuracy[J]. Clin Cancer Res, 2009, 15 (17): 5494-5502. doi: 10.1158/1078-0432.CCR-09-0113
[5]	Meyer PN, Fu K, Greiner TC, Smith LM, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuselarge B-cell lymphoma treated with rituximab[J]. J Clin Oncol, 2011, 29(2): 200-207. doi: 10.1200/JCO.2010.30.0368
[6]	Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal centerB-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma[J]. J Clin Oncol, 2008, 26 (28): 4587-4594. doi: 10.1200/JCO.2007.15.9277
[7]	Chen Y, Han T, Iqbal J, et al. Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases[J]. Am J Clin Pathol, 2010, 133(2): 305-313. doi: 10.1309/AJCP4H6ADGYDZMOA
[8]	Song Y, Cao Z, Li L, et al. Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and theirinterrelation[J]. Chin J Cancer, 2010, 29(9): 781-786. doi: 10.5732/cjc.010.10082
[9]	赵菁, 赵静, 蔡莺莺, 等. BCL-6基因5'非编码区突变与弥漫性大B细胞淋巴瘤生发中心亚型的相关性[J]. 中华病理学杂志, 2010, 39(9): 595-599. doi: 10.3760/cma.j.issn.0529-5807.2010.09.005
[10]	罗东兰, 刘艳辉, 庄恒国, 等. 弥漫性大B细胞淋巴瘤500例构成比及免疫表型分析[J]. 中华病理学杂志, 2011, 40(4): 235-239.
[11]	曾丽平, 文亦磊, 马韵, 等. 凋亡抑制基因BCL-2在弥漫性大B细胞淋巴瘤中的表达及其临床意义[J]. 中华病理学杂志, 2011, 40(6): 377-381. doi: 10.3760/cma.j.issn.0529-5807.2011.06.005
[12]	林莉, 闵敏, 毕成峰, 等. 原发胃肠道弥漫性大B细胞淋巴瘤的免疫分型及其与预后的关系[J]. 中华病理学杂志, 2011, 40(4): 220-226. doi: 10.3760/cma.j.issn.0529-5807.2011.04.002
[13]	张宏伟, 陈振文, 王晋芬, 等. CD138在弥漫大B细胞淋巴瘤免疫分型构建及预后评估中的意义[J]. 中华肿瘤杂志, 2011, 33(2): 115-120.
[14]	Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile[J]. Blood, 2002, 99(7): 2285-2290. doi: 10.1182/blood.V99.7.2285
[15]	Barrans SL, Evans PA, O'Connor SJ, et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is astrong predictor of outcome[J]. Clin Cancer Res, 2003, 9(6): 2133-2139. http://pdfs.semanticscholar.org/4835/b6feda5fc451a870ed67bd761dbaad8e55d0.pdf
[16]	Iqbal J, Neppalli VT, Wright G, et al. Bcl2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-celllymphoma[J]. J Clin Oncol, 2006, 24(6): 961-968. doi: 10.1200/JCO.2005.03.4264
[17]	Iqbal J, Greiner TC, Patel K, et al. Distinctive patterns of Bcl6 molecular alterations and their functional consequences in differentsubgroups of diffuse large B-cell lymphoma[J]. Leukemia, 2007, 21 (11): 2332-2343. doi: 10.1038/sj.leu.2404856
[18]	Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive[J]. Blood, 2003, 101(3): 1149-1154. doi: 10.1182/blood.V101.3.1149
[19]	Kim MK, Bae SH, Bae YK, et al. Biological characterization of nodal versus extranodal presentation of diffuse large B-Celllymphoma using immunohistochemistry[J]. Clin Lymphoma Myeloma Leuk, 2011, 11(5): 403-408. doi: 10.1016/j.clml.2011.05.037
[20]	Shiozawa E, Yamochi-Onizuka T, Takimoto M, et al. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries[J]. Leuk Res, 2007, 31(11): 1579-1583. doi: 10.1016/j.leukres.2007.03.017